long intergenic non-protein coding RNA 2625Genealiases: []
Q-omics provides the consensus-scored LINC02625 profile across patient tissues and cancer cell-line models. LINC02625 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02625 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, LINC02625 RNA expression shows 9,783 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where LINC02625 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02625 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02625 survival associations across molecular data types. LINC02625 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02625 RNA expression–survival associations across cancer types. High LINC02625 expression shows unfavorable associations in ESCA, LGG and READ, but favorable associations in KIRC, UVM and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02625 RNA expression.
This table summarizes LINC02625 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02625. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02625 shows lower tumor expression in KICH, THCA, LUSC and BRCA and higher tumor expression in LUAD and LIHC. The KICH box plot shows higher LINC02625 RNA expression in normal versus tumor tissue (log2 FC = −0.929, t-test p < 0.001).
This table shows molecular features associated with LINC02625 in patient tissues and cancer cell lines. In patient samples, LINC02625 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
